Delving into the Latest Updates on Ipilimumab with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Anti CTLA-4 monoclonal antibody, Anti-CTLA-4 Mab, Ipilimumab (Genetical Recombination)

+ [16]

Target

CTLA4

Action

inhibitors

Mechanism

CTLA4 inhibitors(Cytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors)

Therapeutic Areas

NeoplasmsDigestive System DisordersRespiratory Diseases+ [12]

Active Indication

Advanced Hepatocellular CarcinomaUnresectable Hepatocellular CarcinomaMismatch repair-deficient Colonic Cancer+ [303]

Inactive Indication

Acute lymphoblastic leukemia recurrentAcute myeloid leukaemia with 11q23 abnormalityAcute Promyelocytic Leukemia+ [96]

Originator Organization

Bristol Myers Squibb Co.

Active Organization

Bristol Myers Squibb Co.

National Cancer InstituteBristol-Myers Squibb Pharma EEIG

+ [10]

Inactive Organization

Checkmate Pharmaceuticals, Inc.National Institutes of Health Clinical Center

Syndax Pharmaceuticals, Inc.

+ [4]

Drug Highest PhaseApproved

First Approval Date

United States (25 Mar 2011),

Melanoma

RegulationFast Track (United States), Accelerated Approval (United States), Orphan Drug (United States), Priority Review (China), Breakthrough Therapy (China), Conditional marketing approval (China), Orphan Drug (South Korea), Priority Review (Australia), Priority Review (United States), Breakthrough Therapy (United States)

Login to view timeline

Structure/Sequence

Sequence Code 143797L

Source: *****

Sequence Code 9060585H

Source: *****

Testing of candidate monoclonal antibody therapeutics in preclinical models is an essential step in drug development. Identification of antibody therapeutic candidates that bind their human targets and cross-react to mouse orthologs is often challenging, especially for targets with low sequence homology. In such cases, surrogate antibodies that bind mouse orthologs must be used. The antibody 9D9, which binds mouse CTLA-4, is a commonly used surrogate for CTLA-4 checkpoint blockade studies in mouse cancer models. In this work, we reveal that 9D9 has significant biophysical dissimilarities to therapeutic CTLA-4 antibodies. The 9D9-mCTLA4 complex crystal structure was determined and shows that the surrogate antibody binds an epitope distinct from ipilimumab and tremelimumab. In addition, while ipilimumab has pH-independent binding to hCTLA-4, 9D9 loses binding to mCTLA-4 at physiologically relevant acidic pH ranges. We used phage and yeast display to engineer ipilimumab to bind mouse CTLA-4 with single-digit nM affinity from an initial state with no apparent binding. The engineered variants showed pH-independent and cross-reactive binding to both mouse and human CTLA-4. Crystal structures of a variant in complex with both mouse and human CTLA-4 confirmed that it targets an equivalent epitope as ipilimumab. These cross-reactive ipilimumab variants may facilitate improved translatability and future mechanism-of-action studies for anti-CTLA-4 targeting in murine models.

31 Dec 2025·OncoImmunology

Circulating cytokine associations with clinical outcomes in melanoma patients treated with combination nivolumab plus ipilimumab

Article

Author: Baginska, Joanna ; Rodig, Scott J. ; Severgnini, Mariano ; Hodi, F. Stephen ; Chen, Jiajia ; Manuszak, Claire ; Brennick, Ryan ; Weirather, Jason L. ; Manos, Michael ; Ranasinghe, Srinika ; Liu, David ; Huang, Amy Y. ; Holovatska, Marta ; Hathaway, Emma ; Nazzaro, Matthew ; Giobbie-Hurder, Anita ; Tarantino, Giuseppe ; Pfaff, Kathleen L. ; Russell, Janice D.

Nivolumab plus ipilimumab (aCTLA-4/aPD-1) combination therapy has significantly improved clinical outcomes in patients with metastatic melanoma, with 50%-60% of patients responding to treatment, but predictors of response are poorly characterized. We hypothesized that circulating cytokines and peripheral white blood cells may predict response to therapy and evaluated 15 cytokines and complete blood counts (CBC with differentials) from 89 patients with advanced melanoma treated with combination therapy from three points in time: pre-treatment, one month and approximately three months after starting therapy. Clinical endpoints evaluated included durable clinical benefit (DCB), progression-free survival (PFS), and overall survival (OS). A parsimonious predictive model was developed to identify cytokines predictors of response to combination therapy. In this study, we found that pre-treatment, patients with DCB had higher IL-23, lower CXCL6, and lower IL-10 levels. Lower NLR one month after starting therapy predicted better PFS and OS, primarily driven by an increase in absolute lymphocytes. A multivariate model demonstrated that baseline CXCL6, IL-10, IL-23 were independent predictors of therapy response, and the combined model has reached an area under the curve (AUC) of 0.79 in prediction of response to combination therapy. Our study identified baseline CXCL6, IL-23, and IL-10 as predictors of response to aCTLA4/aPD1 combination therapy among patients with metastatic melanoma. This study also provides a framework for identifying patients who are likely to respond to combination ICB, as well as a subset of patients with high risk of developing resistance and are thus in need of alternative therapeutic options, such as clinical trials.

31 Dec 2025·OncoImmunology

Impact of steroid dose and timing on efficacy of combination PD-1/CTLA-4 blockade

Article

Author: Burnette, Hannah R. ; Czapla, Juliane Andrade ; Cui, Can ; Curkovic, Nina B. ; Lawless, Aleigha R. ; Irlmeier, Rebecca ; Ye, Fei ; Sullivan, Ryan ; Johnson, Douglas B. ; Bai, Xue

With the increasing use of immune checkpoint inhibitors (ICIs) in combination regimens and in earlier stages of advanced melanoma, the effective management of immune-related adverse events (irAEs) is key to balancing immunotherapy efficacy and toxicity. Conflicting evidence exists on possible detrimental effects of immunosuppression with corticosteroids for irAEs on ICI effectiveness. We conducted a multicenter, retrospective cohort study of immunotherapy-naïve advanced melanoma patients undergoing treatment with ipilimumab and nivolumab and a small cohort treated with nivolumab/relatlimab. We utilized univariate tests to assess response, PFS, and OS based on presence of irAE, receipt of steroids for irAEs, peak dose, and time-to-steroid, as well as multivariable analysis for response, OS, and PFS in patients receiving steroids for irAEs. Among 226 total ipilimumab/nivolumab patients, those without irAEs had poorer PFS and OS compared to irAE groups regardless of steroid administration. In subgroup analysis of patients receiving steroids for an irAE, increased time-to-steroid was significantly associated with improved response (aOR, 1.026 p = 0.0005), PFS (aHR, 0.986 p = 0.001), and OS (aHR, 0.983 p = 0.0008). Higher peak steroid dose was significantly associated with poorer PFS (aHR, 1.002 p = 0.005), and OS (aHR, 1.002 p = 0.003). Use of additional immunosuppressants was associated with poorer OS (aHR, 1.941 p = 0.018). Cumulative dose was not significantly associated with outcomes. Among 42 additional patients treated with nivolumab/relatlimab, irAEs were significantly associated with improved PFS/OS, which appeared to be slightly mitigated by steroid administration; dosing relationships were limited by small numbers.

837

News (Medical) associated with Ipilimumab

29 Apr 2025

·www.globenewswire.com

Sandoz enters global collaboration license agreement with Henlius to commercialize leading oncology therapy, ipilimumab, in multiple indications

MEDIA RELEASE Agreement offers rights to commercialize proposed biosimilar of Yervoy®* for treatment of variety of cancer types, targeting net reference medicine sales of USD 2.5 billion[1]Henlius to develop and manufacture biosimilar, with Sandoz to register and commercialize after expiry of relevant patents across global marketsCombination therapy of ipilimumab and nivolumab used in 95% of eligible patients[2]; ipilimumab highly complementary to proposed Sandoz nivolumab biosimilarPotential to address considerable unmet medical needs and increase worldwide access; reinforces Sandoz commitment to expand patient access and drive sustainable savings for healthcare systems Basel, April 29, 2025 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, announced today that it has signed a global collaboration agreement with Shanghai Henlius Biotech, Inc. (Henlius, HKEX:02696) to commercialize a biosimilar of leading oncology therapy, ipilimumab. The agreement is milestone-based for a total consideration of up to USD 301 million, including an upfront payment of USD 31 million, and will target net reference-medicine sales of USD 2.5 billion[1]. Under the terms of the agreement, Sandoz has exclusive commercial rights for a biosimilar of ipilimumab in Australia, Canada, Europe, Japan and the US. The core sequence patent for ipilimumab expired in March 2025 in the US and will expire no later than February 2026 in the EU. Richard Saynor, CEO of Sandoz, said: “The global burden of cancer continues to grow and the potential to address unmet patient needs has never been greater.[3] This agreement offers us the chance to reach many more millions of patients, while helping to drive the long-term sustainability of healthcare systems.” The reference medicine, ipilimumab, is a monoclonal (CTLA-4) antibody-blocking medication, which is used alone or with other medicines to treat certain types of colorectal cancer, esophageal cancer, hepatocellular carcinoma (a type of liver cancer), malignant pleural mesothelioma, melanoma, non-small cell lung cancer, and renal cell carcinoma (a type of kidney cancer).[4,5,6] Henlius is developing its own proposed biosimilar of ipilimumab in an integrated Phase I/III trial in the unresectable hepatocellular carcinoma setting, targeting 656 patients to be enrolled (NCT06841185). Sandoz is developing its own proposed biosimilar of nivolumab in an integrated Phase I/III trial in the advanced melanoma setting, targeting 720 patients to be enrolled (NCT06587451). The reference medicine, nivolumab, (Opdivo®**) is a monoclonal (PD-1) antibody-blocking medication, which is used alone or with other medicines to treat more than 10 different cancer types. In combination with ipilimumab, nivolumab is indicated for the treatment of melanoma, malignant pleural mesothelioma, renal cell carcinoma, certain types of colorectal cancer, esophageal cancer, non-small cell lung cancer and hepatocellular carcinoma.[7,8] Sandoz is the leading biosimilar provider globally and has recently moved up to third position in the US, with a strategic ambition to occupy the leading position in that market.[9] The Company’s industry-leading biosimilars pipeline comprises 28 molecules, complemented by around 450 generic pipeline medicines to support its goal of sustainable and broadly-based long-term growth. The marketed biosimilar oncology portfolio includes Rixathon®, Zarzio®, Ziextenzo®, and Binocrit®. This year, Sandoz expects to launch its biosimilars Wyost®/Jubbonti® (denosumab) in the US in the second quarter and in Europe in the fourth quarter. * Yervoy® is a registered trademark of Bristol-Myers Squibb (US)** Opdivo® is a registered trademark of Bristol-Myers Squibb (US) DISCLAIMERThis Media Release contains forward-looking statements, which offer no guarantee with regard to future performance. These statements are made on the basis of management’s views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside of the control of Sandoz. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Each forward-looking statement speaks only as of the date of the particular statement, and Sandoz undertakes no obligation to publicly revise any forward-looking statements, except as required by law. REFERENCES1. Loss-of-exclusivity (LoE) dates based on IP databases; originator-sales data at LoE-1 from internal analysis and Evaluate Pharma [November 2024]2. Decisions Resource Group (DRG) database of total treated population with Yervoy® (G7 markets) [accessed April 2025]3. Cancer Today [accessed March 2025]4. Yervoy® US Prescribing Information [accessed March 2025]5. Yervoy® EMEA Summary of Product Characteristics [accessed March 2025]6. Definition of Yervoy® - NCI Dictionary of Cancer Terms - NCI [accessed March 2025]7. Opdivo® US: Prescribing Information [accessed March 2025]8. Opdivo® EMEA Summary of Product Characteristics [accessed March 2025]9. IQVIA [download February 2025] ABOUT SANDOZSandoz (SIX: SDZ; OTCQX: SDZNY) is the global leader in generic and biosimilar medicines, with a growth strategy driven by its Purpose: pioneering access for patients. More than 20,000 people of 100 nationalities work together to ensure 900 million patient treatments are provided by Sandoz, generating substantial global healthcare savings and an even larger social impact. Its leading portfolio of approximately 1,300 products addresses diseases from the common cold to cancer. Headquartered in Basel, Switzerland, Sandoz traces its heritage back to 1886. Its history of breakthroughs includes Calcium Sandoz in 1929, the world’s first oral penicillin in 1951, and the world’s first biosimilar in 2006. In 2024, Sandoz recorded net sales of USD 10.4 billion. CONTACTS Global Media RelationsInvestor RelationsGlobal.MediaRelations@sandoz.comInvestor.Relations@sandoz.comAlex Kalomparis+41 79 279 0285Craig Marks+44 7818 942 383Joerg E. Allgaeuer+49 171 838 4838Rupreet Sandhu+41 79 410 5472 Attachment Media release_collaboration license agreement

License out/in

28 Apr 2025

·www.prnewswire.com

AVEO Oncology, an LG Chem company, Announces Three Poster Presentations at ASCO 2025 Annual Meeting

BOSTON, April 28, 2025 /PRNewswire/ -- AVEO Oncology, an LG Chem company ("AVEO"), a biopharmaceutical company committed to providing differentiated solutions to improve cancer patients lives, announced today that three abstracts were accepted for presentation at the upcoming American Society of Clinical Oncology (ASCO) 2025 annual meeting this May 30-June 3, 2025, in Chicago, IL. Presentation Details Title: Efficacy of second line (2L) treatment with tivozanib (Tivo) as monotherapy or with nivolumab (Nivo) in patients (pts) with metastatic renal cell carcinoma (mRCC) previously treated with an immune checkpoint inhibitor (ICI) combination of ipilimumab (Ipi)/Nivo or vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFR-TKI)/ICI in the Phase 3 TiNivo-2 study First Author: Alexander Chehrazi-Raffle, MD, City of Hope Cancer Center Abstract Number: 4540 Poster Session: Genitourinary Cancer—Kidney and Bladder Poster Board: 340 Date and Time: Monday, June 2, 2025, 9:00am – 12:00 PM CDT Title: FIERCE-HN: A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of ficlatuzumab (HGF/cMET Mab) in combination with cetuximab in participants with recurrent or metastatic (R/M) HPV negative head and neck squamous cell carcinoma (HNSCC) First Author: Julie E. Bauman, MD, MPH, George Washington University Cancer Center Abstract Number: TPS6115 Poster Session: Head and Neck Cancer Poster Board: 520a Date and Time: Monday, June 2, 2025, 9:00 AM – 12:00 PM CDT Title: A phase1b dose escalation study of AV-380 (anti-GDF15 monoclonal antibody) in combination with standard-of-care therapy in cancer patients with cachexia First Author: Eric Roeland, MD, FAAHPM, Oregon Health & Science University Abstract Number: TPS12142 Poster Session: Symptom Science and Palliative Care Poster Board: 159a Date and Time: Monday, June 2, 2025, 1:30-4:30 PM CDT About AVEO Pharmaceuticals, Inc. AVEO is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. AVEO currently markets FOTIVDA® (tivozanib) in the U.S. for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. AVEO and its strategic partners continue to develop FOTIVDA in other novel targeted combinations in RCC. The company also has investigational programs in other areas of high unmet need, including ficlatuzumab in HPV-negative refractory head and neck squamous cell carcinoma and AV-380 in cancer cachexia. AVEO became a wholly owned subsidiary of LG Chem Life Sciences USA, Inc. on January 19, 2023. AVEO continues to operate under the AVEO Oncology, an LG Chem company, name. About LG Chem, Ltd. and LG Chem Life Sciences LG Chem, Ltd. (LG Chem) is a leading global chemical company with a diversified business portfolio in the key areas of petrochemicals, advanced materials, and life sciences. The company manufactures a wide range of products from high-value added petrochemicals to renewable plastics, specializing in cutting- edge electronic and battery materials, as well as drugs and vaccines to deliver differentiated solutions for its customers. LG Chem Life Sciences develops, manufactures, and globally commercializes pharmaceutical products, with a focus on Oncology, Immunology, and Metabolic diseases. Our mission is to transform people's lives through inspiring science and leading innovation. For more information, please visit . Contacts Media: John F. Kouten JFK Communications, Inc. [email protected] (908) 227-4714 SOURCE AVEO, an LG Chem company WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

ImmunotherapyDrug ApprovalASCOPhase 3

23 Apr 2025

·pmlive.com

BMS receives NICE recommendation for immunotherapy combination in colorectal cancer

Bristol Myers Squibb (BMS) has announced that its dual immunotherapy combination has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line treatment for a subset of colorectal cancer patients. The health technology assessment agency has recommended in final draft guidance that Opdivo (nivolumab) plus Yervoy (ipilimumab) be used on the NHS in England, Wales and Northern Wales to treat adults with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) unresectable or metastatic colorectal cancer. Approximately 44,000 people in the UK are diagnosed with colorectal cancer, also known as bowel cancer, every year. Up to 7% of patients with metastatic disease have dMMR or MSI-H tumours and, as a result, are less likely to benefit from conventional chemotherapy and typically have a poor prognosis. NICE’s decision, which comes after the Medicines and Healthcare products Regulatory Agency granted an indicated extension to the combination earlier this month, is supported by positive results from the phase 3 CheckMate 8HW trial. In the study, progression-free survival at 24 months was 72% with Opdivo plus Yervoy compared to 14% with investigator’s choice of chemotherapy in the first-line setting. The safety profile of the combination was also found to be consistent with previously reported data, with no new safety signals identified. Guy Oliver, UK and Ireland general manager at BMS, said: “We know that cancer patients benefit from access to innovative treatments, and this is a significant milestone for eligible unresectable or metastatic colorectal cancer patients in England, Wales and Northern Ireland.” Sharing a similar sentiment, Kai-Keen Shiu, consultant medical oncologist at University College London Hospitals NHS Foundation Trust said the recommendation “marks a major advancement for patients living with MSI-H/dMMR metastatic colorectal cancer”. “This dual immunotherapy regimen offers a meaningful alternative to existing treatments and improved quality of life for these patients versus chemotherapy,” Shiu added. NICE’s decision comes just two weeks after the US Food and Drug Administration approved Opdivo plus Yervoy as a first-line treatment for adult and paediatric patients aged 12 years and older with unresectable or metastatic MSI-H or dMMR colorectal cancer. The Opdivo/Yervoy combination was also recently approved by the FDA as a first-line treatment for adults with unresectable or advanced cases of hepatocellular carcinoma, the most common type of liver cancer.

Clinical ResultImmunotherapyPhase 3Drug Approval

100 Deals associated with Ipilimumab

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D04603	Ipilimumab	L01XC11	DB06186

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Advanced Hepatocellular Carcinoma	European Union	Bristol Myers Squibb Co.	08 Mar 2025
Advanced Hepatocellular Carcinoma	Iceland	Bristol Myers Squibb Co.	08 Mar 2025
Advanced Hepatocellular Carcinoma	Liechtenstein	Bristol Myers Squibb Co.	08 Mar 2025
Advanced Hepatocellular Carcinoma	Norway	Bristol Myers Squibb Co.	08 Mar 2025
Unresectable Hepatocellular Carcinoma	European Union	Bristol Myers Squibb Co.	08 Mar 2025
Unresectable Hepatocellular Carcinoma	Iceland	Bristol Myers Squibb Co.	08 Mar 2025
Unresectable Hepatocellular Carcinoma	Liechtenstein	Bristol Myers Squibb Co.	08 Mar 2025
Unresectable Hepatocellular Carcinoma	Norway	Bristol Myers Squibb Co.	08 Mar 2025
Mismatch repair-deficient Colonic Cancer	European Union	Bristol-Myers Squibb Pharma EEIG	13 Jan 2025
Mismatch repair-deficient Colonic Cancer	Iceland	Bristol-Myers Squibb Pharma EEIG	13 Jan 2025
Mismatch repair-deficient Colonic Cancer	Liechtenstein	Bristol-Myers Squibb Pharma EEIG	13 Jan 2025
Mismatch repair-deficient Colonic Cancer	Norway	Bristol-Myers Squibb Pharma EEIG	13 Jan 2025
Unresectable Esophageal Squamous Cell Carcinoma	United States	Bristol Myers Squibb Co.	27 May 2022
Esophageal Carcinoma	Japan	Bristol-Myers Squibb KK	26 May 2022
Mesothelioma	Japan	Ono Pharmaceutical Co., Ltd.	27 May 2021
Mesothelioma	Japan	Bristol-Myers Squibb KK	27 May 2021
Hepatocellular Carcinoma	United States	Bristol Myers Squibb Co.	10 Mar 2020
Melanoma, Cutaneous Malignant	United States	Bristol Myers Squibb Co.	10 Jul 2018
Colorectal Cancer	United States	Bristol Myers Squibb Co.	16 Apr 2018
Advanced Renal Cell Carcinoma	European Union	Bristol-Myers Squibb Pharma EEIG	13 Jul 2011

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Bladder Cancer	Phase 3	United States	Ono Pharmaceutical Co., Ltd.	30 Jan 2022
Bladder Cancer	Phase 3	United States	Sino-American Shanghai Squibb Pharmaceuticals Ltd.	30 Jan 2022
HER2 negative Gastric Cancer	Phase 3	Japan	Ono Pharmaceutical Co., Ltd.	05 Nov 2021
HER2 negative Gastric Cancer	Phase 3	South Korea	Ono Pharmaceutical Co., Ltd.	05 Nov 2021
HER2 negative Gastric Cancer	Phase 3	Taiwan Province	Ono Pharmaceutical Co., Ltd.	05 Nov 2021
Glioblastoma	Phase 3	United States	National Cancer Institute	01 Sep 2020
Gliosarcoma	Phase 3	United States	National Cancer Institute	01 Sep 2020
Locally Advanced Lung Non-Small Cell Carcinoma	Phase 3	United States	Bristol Myers Squibb Co.	08 Oct 2019
Locally Advanced Lung Non-Small Cell Carcinoma	Phase 3	China	Bristol Myers Squibb Co.	08 Oct 2019
Locally Advanced Lung Non-Small Cell Carcinoma	Phase 3	Japan	Bristol Myers Squibb Co.	08 Oct 2019

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04938232 (CTgov)	Phase 2	Relapsing classical Hodgkin lymphoma \| Refractory Hodgkin Lymphoma	13	ipilimumab+Nivolumab	yplqmvsknm = qwsifpmizq xgzhspfpvh (ayorfdyhrm, ezoskdgccz - cedkndgsgu) View more	-	03 Apr 2025
ESMO_ELCC2025	Not Applicable	Mesothelioma, Malignant First line	399	Ipilimumab plus Nivolumab	mezcbrgooj(egpcejssxa) = required in over half (53%) of TRAEs mspbamlavi (wuxajvjicu ) View more	Positive	26 Mar 2025
RW-9LA (ESMO_ELCC2025)	Not Applicable	Advanced Lung Non-Small Cell Carcinoma programmed death-ligand (PD-L1) negative	40	Ipilimumab/Nivolumab + Chemotherapy	kgabrhyzbf(fgljewzrza) = eyxrkldymw uwoqhzgfku (mpplgxgaks ) View more	Positive	26 Mar 2025
NCT03377023 (CTgov)	Phase 1/2	metastatic non-small cell lung cancer	66	Ipilimumab+Nivolumab+Nintedanib (Phase 1-Dose Escalation)	cjpwgyroop = gfpduomajf bddscsrucq (jasdozoqmc, yoajibbevz - hbbgurlnnw)	-	25 Mar 2025
				ipilimumab+Nivolumab+Nintedanib (Phase 2 - Arm A)	msngvtrntr = qmivkbkvqg srdrljzoou (xmddtkjgkr, wsgtznnvqb - vssgpqlrzp) View more
NCT02488759 (CheckMate 358, Pubmed \| J Clin Oncol)	Phase 1/2	Metastatic Merkel Cell Carcinoma	-	Nivolumab	yhjvlkhglw(bwfhbkylha) = mdwrhgienj ibpamqoyiy (ffhzvjoweu, 38.7 - 78.9) View more	Negative	20 Mar 2025
				Nivolumab + Ipilimumab	yhjvlkhglw(bwfhbkylha) = haeqspmnrl ibpamqoyiy (ffhzvjoweu, 42.1 - 73) View more
NCT03285321 (BTCRC-LUN16-081 \| BTCRC LUN 16-081, CTgov)	Phase 2	Unresectable Lung Non-Small Cell Carcinoma	105	Nivolumab (Arm 1: Nivolumab)	sfpbgisboh = usmgkrlriy ymohlckxmx (pxwsahvudv, aqiybiqjxn - pdnjijexly) View more	-	11 Mar 2025
				Ipilimumab+Nivolumab (Arm 2: Nivolumab Plus Ipilimumab)	sfpbgisboh = gzambikmqx ymohlckxmx (pxwsahvudv, mfoaflpeyu - ilkwwfrvmb) View more
NCT03158129 (NEOSTAR, CTgov)	Phase 2	Non-small cell lung cancer stage I \| Non-small cell lung cancer stage IIIA \| Non-small cell lung cancer stage II	101	Nivolumab (Arm A - Nivolumab)	zahayrahdu = gsbqbozitl gmezsumpfw (edpdqiimzh, mxklzuobya - qeshvnjulh) View more	-	05 Mar 2025
				Ipilimumab+Nivolumab (Arm B - Nivolumab + Ipilimumab)	zahayrahdu = yxbdginete gmezsumpfw (edpdqiimzh, gwvblgkwdq - qseesqinnn) View more
NCT04134182 (ASCO_GU2025) Manual	Phase 2	Renal Cell Carcinoma	8	Nivolumab + Ipilimumab	pwhuttrvba(qfepcixpgn) = jqzyktnwgi jejiwwtouc (icuulfqlvd ) View more	Positive	13 Feb 2025
ASCO_GU2025 Manual	Not Applicable	Metastatic Renal Cell Carcinoma Maintenance \| First line	222	Four Doses of IPI + NIVO	zdfycvygui(ejlgznbinm) = auifcpjuer gsfknluotx (scihsexqsu, 82 - 93) View more	Positive	13 Feb 2025
				Fewer Than Four Doses of IPI + NIVO	zdfycvygui(ejlgznbinm) = wnlncsjtwu gsfknluotx (scihsexqsu, 72 - 94) View more
NCT05014776 (CTgov)	Phase 2	Pancreatic adenocarcinoma metastatic \| Metastatic Pancreatic Cancer	17	CRS-207+ipilimumab+pembrolizumab+Tadalafil	gcoitvlgsp = cprdykyuth nprosnpjvf (hxvcxetree, fqoobsbjer - qzthomzowx) View more	-	30 Jan 2025

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.

login

or

view full example data

Understand key drug designations in just a few clicks with Synapse.

Ipilimumab

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation